Stay updated on Pfizer Press Releases

Sign up to get notified when there's something new on the Pfizer Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Pfizer Press Releases page

  1. Check
    2 days ago
    Change Detected
    Summary
    Pfizer has added a new research update on Sasanlimab's effectiveness in treating high-risk non-muscle invasive bladder cancer and a financial webcast invitation for January 2025, while previous webcast invitations from November 2024 have been removed.
    Difference
    20%
    Check dated 2025-01-12T07:05:42.000Z thumbnail image
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    Change Detected
    Summary
    The U.S. FDA has approved Pfizer’s BRAFTOVI® combination regimen for the first-line treatment of BRAF V600E-mutant metastatic colorectal cancer, while the previous report on Pfizer's strong third-quarter results has been removed.
    Difference
    9%
    Check dated 2024-12-28T23:19:31.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    Pfizer has announced a webcast for its February 4 conference call and provided full-year guidance for 2024 and 2025, while recent approvals and recommendations for its vaccines have been removed from the site.
    Difference
    19%
    Check dated 2024-12-21T17:03:02.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    Pfizer has announced its first-quarter 2025 dividend and reported promising results from a Phase 3 study of IBRANCE® for metastatic breast cancer, while notable deletions include the approval of HYMPAVZI™ for hemophilia and the election of Tim Buckley to the board.
    Difference
    47%
    Check dated 2024-12-14T12:04:39.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    Pfizer has showcased its scientific leadership in breast cancer and blood disorders with over 100 presentations at ASH and SABCS in December 2024, while the announcement of its fourth-quarter 2024 dividend has been removed.
    Difference
    9%
    Check dated 2024-12-07T09:55:05.000Z thumbnail image
  7. Check
    53 days ago
    Change Detected
    Summary
    Pfizer has announced a new Chief Scientific Officer and received European Commission approval for its treatment HYMPAVZI™ for severe Hemophilia A or B, while several navigation elements and past news items have been removed from the website.
    Difference
    34%
    Check dated 2024-11-23T03:33:51.000Z thumbnail image

Stay in the know with updates to Pfizer Press Releases

Enter your email address, and we'll notify you when there's something new on the Pfizer Press Releases page.